191 related articles for article (PubMed ID: 35131317)
21. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging.
Danti G; Flammia F; Matteuzzi B; Cozzi D; Berti V; Grazzini G; Pradella S; Recchia L; Brunese L; Miele V
Radiol Med; 2021 Dec; 126(12):1497-1507. PubMed ID: 34427861
[TBL] [Abstract][Full Text] [Related]
23. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
24. Guideline for PET/CT imaging of neuroendocrine neoplasms with
Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1588-1601. PubMed ID: 28547177
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective.
Ma X; Ding Y; Li W; Li Q; Yang H
Front Oncol; 2022; 12():1061065. PubMed ID: 36483036
[TBL] [Abstract][Full Text] [Related]
26. Peptide Receptor Radionuclide Therapy.
Hofland J; Brabander T; Verburg FA; Feelders RA; de Herder WW
J Clin Endocrinol Metab; 2022 Nov; 107(12):3199-3208. PubMed ID: 36198028
[TBL] [Abstract][Full Text] [Related]
27. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
28. [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms].
Hommann M; Kaemmerer D; Hörsch D; Kulkarni HR; Robiller F; Baum RP
Chirurg; 2014 Jun; 85(6):500-4. PubMed ID: 24844432
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias.
Remes SM; Leijon HL; Vesterinen TJ; Arola JT; Haglund CH
J Histochem Cytochem; 2019 Oct; 67(10):735-743. PubMed ID: 31381461
[TBL] [Abstract][Full Text] [Related]
30. Molecular Imaging and Therapy for Neuroendocrine Tumors.
Desai H; Borges-Neto S; Wong TZ
Curr Treat Options Oncol; 2019 Aug; 20(10):78. PubMed ID: 31468190
[TBL] [Abstract][Full Text] [Related]
31. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
32. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
Papadakis GZ; Karantanas AH; Marias K; Millo C
Eur J Radiol; 2021 Oct; 143():109932. PubMed ID: 34482177
[TBL] [Abstract][Full Text] [Related]
33. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy.
Pencharz D; Gnanasegaran G; Navalkissoor S
Br J Radiol; 2018 Nov; 91(1091):20180108. PubMed ID: 30102557
[TBL] [Abstract][Full Text] [Related]
34. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin Receptor Imaging PET in Neuroendocrine Neoplasm.
Johnbeck CB; Mortensen J
PET Clin; 2021 Apr; 16(2):191-203. PubMed ID: 33648664
[TBL] [Abstract][Full Text] [Related]
36. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
37. Role of Combined
Kaewput C; Vinjamuri S
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204371
[TBL] [Abstract][Full Text] [Related]
38. Molecular imaging and radionuclide therapy of neuroendocrine tumors.
Haider M; Al-Toubah T; El-Haddad G; Strosberg J
Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):16-21. PubMed ID: 31789833
[TBL] [Abstract][Full Text] [Related]
39. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
[TBL] [Abstract][Full Text] [Related]
40. The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.
Gourni E; Waser B; Clerc P; Fourmy D; Reubi JC; Maecke HR
J Nucl Med; 2014 Jun; 55(6):976-82. PubMed ID: 24744444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
